Scholarlink

Background <p>Prevention of progression into type 2 diabetes (T2D) in patients with prediabetes is a key goal of obesity management. In SURMOUNT-5, once weekly tirzepatide at the maximum tolerated dose (MTD 10&#xa0;mg or 15&#xa0;mg) compared with semaglutide (MTD 1.7&#xa0;mg or 2.4&#xa0;mg) resulted in significantly greater body weight reduction in adults living with obesity without T2D.</p> Purpose <p>Assess changes in glycemia outcomes with tirzepatide (MTD 10&#xa0;mg or 15&#xa0;mg) compared with semaglutide (MTD 1.7&#xa0;mg or 2.4&#xa0;mg) in participants with obesity and prediabetes from SURMOUNT-5.</p> Methods <p>Participants (N = 425) with baseline prediabetes, defined as having ≥ 1 fasting lab-based value of either FSG 100–125&#xa0;mg/dL or HbA1c 5.7–6.4%, were included in this analysis. Change from baseline in HbA1c, proportion of participants achieving normoglycemia (i.e., HbA1c &lt; 5.7% and FSG &lt; 100&#xa0;mg/dL), percent change from baseline in body weight, fasting insulin, estimates of insulin sensitivity (HOMA2-IR), and proportion of participants achieving body weight reduction thresholds (≥ 10% to ≥ 30%) at Week 72 were assessed using MMRM or logistic regression for categorical measures using the efficacy analysis set.</p> Results <p>Mean baseline age was 47&#xa0;years, 63% were female, BMI was 40&#xa0;kg/m<sup>2</sup>, and HbA1c was 5.86%. At Week 72, mean HbA1c reduction was significantly greater with tirzepatide vs semaglutide (-0.60% vs -0.48%; estimated treatment difference [ETD; 95% CI] -0.12% [−0.18, −0.06]; p &lt; 0.001). A greater proportion of tirzepatide-treated participants reverted to normoglycemia (89.9%) vs semaglutide (76.2%). Mean percent body weight reduction was significantly greater with tirzepatide (−21.5% vs -14.5%; ETD −7.1% [−9.1, −5.0]; p &lt; 0.001). Greater improvements in fasting insulin and HOMA2-IR were observed with tirzepatide vs semaglutide (p &lt; 0.001).</p> Conclusion <p>In this post hoc analysis of SURMOUNT-5, a greater proportion of tirzepatide-treated participants with obesity and prediabetes at baseline reverted to normoglycemia compared with semaglutide. Greater improvements in glycemia, estimates of insulin sensitivity and body weight were also observed with tirzepatide.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月20日

查看全文
  • Rodolfo J. Galindo,
  • Louis J. Aronne,
  • Deborah B. Horn,
  • Alexander D. Miras,
  • Julia P. Dunn,
  • Dachuang Cao,
  • Clare J. Lee,
  • Chrisanthi A. Karanikas,
  • Robert J. Heine,
  • Beverly L. Falcon,
  • Georgios K. Dimitriadis

摘要

Background

Prevention of progression into type 2 diabetes (T2D) in patients with prediabetes is a key goal of obesity management. In SURMOUNT-5, once weekly tirzepatide at the maximum tolerated dose (MTD 10 mg or 15 mg) compared with semaglutide (MTD 1.7 mg or 2.4 mg) resulted in significantly greater body weight reduction in adults living with obesity without T2D.

Purpose

Assess changes in glycemia outcomes with tirzepatide (MTD 10 mg or 15 mg) compared with semaglutide (MTD 1.7 mg or 2.4 mg) in participants with obesity and prediabetes from SURMOUNT-5.

Methods

Participants (N = 425) with baseline prediabetes, defined as having ≥ 1 fasting lab-based value of either FSG 100–125 mg/dL or HbA1c 5.7–6.4%, were included in this analysis. Change from baseline in HbA1c, proportion of participants achieving normoglycemia (i.e., HbA1c < 5.7% and FSG < 100 mg/dL), percent change from baseline in body weight, fasting insulin, estimates of insulin sensitivity (HOMA2-IR), and proportion of participants achieving body weight reduction thresholds (≥ 10% to ≥ 30%) at Week 72 were assessed using MMRM or logistic regression for categorical measures using the efficacy analysis set.

Results

Mean baseline age was 47 years, 63% were female, BMI was 40 kg/m2, and HbA1c was 5.86%. At Week 72, mean HbA1c reduction was significantly greater with tirzepatide vs semaglutide (-0.60% vs -0.48%; estimated treatment difference [ETD; 95% CI] -0.12% [−0.18, −0.06]; p < 0.001). A greater proportion of tirzepatide-treated participants reverted to normoglycemia (89.9%) vs semaglutide (76.2%). Mean percent body weight reduction was significantly greater with tirzepatide (−21.5% vs -14.5%; ETD −7.1% [−9.1, −5.0]; p < 0.001). Greater improvements in fasting insulin and HOMA2-IR were observed with tirzepatide vs semaglutide (p < 0.001).

Conclusion

In this post hoc analysis of SURMOUNT-5, a greater proportion of tirzepatide-treated participants with obesity and prediabetes at baseline reverted to normoglycemia compared with semaglutide. Greater improvements in glycemia, estimates of insulin sensitivity and body weight were also observed with tirzepatide.